KMDA Stock Analysis: Buy, Sell, or Hold?
KMDA - Kamada Ltd
$7.17
0.05 (0.70%)
▲
5d:
-4.27%
30d:
-0.55%
90d:
-15.55%
BUY
HIGH Confidence
Analysis Updated: Jul 13, 2026 12:00 AM ET
Earnings: Aug 12, 2026
28d
Get Alerted When KMDA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: KMDA trading at deep discount. Market pricing in -7.7% annual earnings decline, creating value opportunity for patient investors.
✅ BUY SIGNAL: KMDA trading at deep discount. Market pricing in -7.7% annual earnings decline, creating value opportunity for patient investors.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$17.80
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$11.05
35.1% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 14.9x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: KMDA is currently trading at $7.17, which is considered oversold relative to its 30-day fair value range of $7.17 to $7.42. From a valuation perspective, the stock is trading at a discount (Forward PE: 11.7) compared to its historical average (14.9). Remarkably, the market is currently pricing in an annual earnings decline of 7.7% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, KMDA is in a strong downtrend. The price is currently testing key support at $7.03. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $13.00 (+81.3%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, KMDA is in a strong downtrend. The price is currently testing key support at $7.03. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $13.00 (+81.3%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$7.17 -
$7.42
Company Quality Score
61/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
79.5%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 81.3% below Wall St target ($13.00)
Trading Range Analysis
30-Day Trading Range
$7.17 -
$7.42
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$7.03
Resistance Level
$7.71
Current Trend
Strong Downtrend
Technical data as of
Jul 13, 2026
Fundamental Context
Forward P/E (Next Year Est.)
11.69
Wall Street Target
$13.00
(+81.3%)
Revenue Growth (YoY)
2.8%
Profit Margin
11.2%
Valuation Discount vs History
-7.7% cheaper
PE vs Historical
11.7 vs 14.9
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-7.7%
(market-implied from PE analysis)
1-Year Target
$6.62
(-8%)
2-Year Target
$6.11
(-15%)
3-Year Target
$5.64
(-21%)
3-Yr Target (if PE normalizes)
(PE: 12→15)
$7.19
(+0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 21.8, Growth: 43.5%)
$39.44
(+450%)
Base:
(SPY PE: 11.7, Growth: 43.5%)
$21.17
(+195%)
Bear:
(PE: 9.9, Growth: 43.5%)
$17.99
(+151%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (20x PE), but valuation improves significantly next year (12x PE) as earnings recover.
Trailing PE: 20.34 | Current EPS (TTM): $0.35
Bull Case
$13.72
(+91%)
Analyst growth 75.2%, PE expands to 22.4
Base Case
$12.48
(+74%)
Market implied 75.2%, PE stable at 20.3
Bear Case
$4.84
(-33%)
Severe decline -20.0%, PE contracts to 17.3
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 11.7 to 14.9
Stabilization Target:
$9.14
(+27.5%)
PE Expansion Potential:
+27.5%
Share & Embed Analysis
Last updated: July 13, 2026 7:42 PM ET
Data refreshes hourly during market hours. Next update: 8:42 PM
Data refreshes hourly during market hours. Next update: 8:42 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is KMDA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$198 | 67 BUY |
|
ZTS
Zoetis Inc |
BUY
20 analysts |
$116 | 59 HOLD |
|
UTHR
United Therapeutics Corp… |
STRONG BUY
15 analysts |
$664 | 58 HOLD |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$110 | 51 HOLD |
|
BCRX
BioCryst Pharmaceuticals… |
STRONG BUY
12 analysts |
$22 | 55 HOLD |
